You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, B-Cell, Marginal Zone

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

Completed
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • PI3K inhibitor BKM120
  • +3 more
  • Atlanta, Georgia
  • +1 more
Jun 27, 2022

Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

Not yet recruiting
  • Mature B-Cell Neoplasm
  • +25 more
  • (no location specified)
Sep 14, 2022

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +23 more
  • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Marginal Zone Lymphoma Trial in Germany (Obinutuzumab)

Active, not recruiting
  • Marginal Zone Lymphoma
  • Bochum, Germany
  • +15 more
Nov 4, 2022

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Marginal Zone Lymphoma Trial in United States (Ibrutinib, Rituximab, Placebo)

Recruiting
  • Marginal Zone Lymphoma
  • Los Angeles, California
  • +12 more
Nov 29, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

Active, not recruiting
  • Grade 1 Follicular Lymphoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jun 13, 2022

Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia Trial in Australia,

Recruiting
  • Follicular Lymphoma
  • +7 more
  • Louisville, Kentucky
  • +4 more
Mar 11, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Extranodal Marginal

Completed
Has Results
  • Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
  • +2 more
  • Radiation Therapy
  • Houston, Texas
    M D Anderson Cancer Center
Feb 25, 2022

Follicular Lymphoma (Gastric or Duodenal), Marginal Zone Lymphoma (Gastric or Duodenal) Trial in Münster (Radiation Therapy)

Recruiting
  • Follicular Lymphoma (Gastric or Duodenal)
  • Marginal Zone Lymphoma (Gastric or Duodenal)
  • Radiation Therapy
  • Münster, North Rhine-Westphalia, Germany
    Department of Radiation Oncology
Dec 1, 2021

Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Large B-Cell, Diffuse Trial in Spain (Registry of

Recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • Registry of patients (exposure is Cutaneous Lymphoma)
  • Barcelona, Spain
  • +13 more
Mar 15, 2022

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +20 more
  • Scottsdale, Arizona
  • +1 more
May 6, 2022

Marginal Zone Lymphoma and Its Prognostic Role

Recruiting
  • Marginal Zone Lymphoma
    • Dijon, France
    • +22 more
    Jan 17, 2023

    Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

    Not yet recruiting
    • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
    • +21 more
    • Biopsy
    • +8 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Apr 7, 2023

    Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)

    Completed
    Has Results
    • Marginal Zone Lymphoma
    • +2 more
    • Harbin, Heilongjiang, China
    • +3 more
    Oct 26, 2021

    Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

    Withdrawn
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • (no location specified)
    Jun 28, 2023

    Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell Trial in China (LOXO-305)

    Active, not recruiting
    • Leukemia, Lymphoid
    • +6 more
    • Wuhu, Anhui, China
    • +22 more
    Dec 8, 2022

    Marginal Zone Lymphoma Trial in Austria, Italy, Switzerland (Tafasitamab, Acalabrutinib)

    Recruiting
    • Marginal Zone Lymphoma
    • Wien, Austria
    • +9 more
    Jul 13, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

    Recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +20 more
    • Chimeric Antigen Receptor T-Cell Therapy
    • +4 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jul 11, 2022

    Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide,

    Recruiting
    • Follicular Lymphoma and Marginal Zone Lymphoma
    • Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
    • lenalinomide
    • Beijing, China
      Chinese Academy of Medical Sciences and Peking Union Medical Col
    Feb 13, 2022